NexGard Spectra® protects against all of these key parasites in a single chew
Activity against key dog parasites§
| NexGard Spectra® | Advocate® | Bravecto® | Simparica TrioTM | CredelioTM Plus | |
|---|---|---|---|---|---|
| Fleas | ✓ | ✓ | ✓ | ✓ | ✓ |
| Ticks | ✓ | ✓ | ✓ | ✓ | |
| Mites | ✓ | ✓ | ✓ | ✓ |  |
| Roundworms | ✓ | ✓ | ✓ | ✓ | |
| Lungworm | ✓ | ✓ | ✓ | ✓ |
Hear why practices are choosing NexGard Spectra®
For more information, read the full vet brochure
Explore the latest...
One and Done owner materials
Handy resources, like posters for your veterinary practice, and materials to support your client communications.
Puppy campaign
Engage with new puppy owner clients, helping to keep their new family member happy and healthy while building a lifelong connection with your practice.
Introducing Parassess®
A FREE online, easy-to-use parasite risk checker that helps owners to help you assess their dog’s individual risk. Enables a timely, risk-based prescribing decision in your busy practice.
Explore our latest programme of focused practice support, WHAT'S THE RISK?, designed to help you implement risk-based prescribing in your busy practice and be in with a chance to WIN AN APPLE® BUNDLE for yourself plus an iPad® for your practice*
* Terms and conditions apply, available at whatstherisk.co.uk or alternatively please call 01344 746957 (UK) or 01 291 3985 (Ireland) or email vetenquiries@boehringer-ingelheim.com for more information and to access a copy. Apple® and iPad® are registered trademarks of Apple Inc., registered in the U.S. and other countries and regions.
- One and Done owner materials
- Puppy campaign
- Parassess risk checker
- Learn and win an Apple Bundle
Choose NexGard Spectra®...
-
for dogs
Learn more -
for owners
Learn more -
for practices
Learn more
* Terms and conditions apply, which are available from the contact details below.
** GFK Data List Price Sales. January 2022 to October 2022.
† NexGard Spectra® also covers heartworm, hookworms, whipworm and eyeworm. NexGard Spectra®’s mite indication is for treatment of sarcoptic mange, demodicosis and otodectes cynotis. NexGard Spectra® does not cover tapeworm.
†† Caused by Otodectes cynotis.
‡The safety of the veterinary medicinal product has not been established in breeding males. In breeding males, use only according to the benefit-risk assessment by the responsible veterinarian.
§ The table shows activity against fleas, ticks, roundworms, lungworm and mites (sarcoptic and demodectic mange only). Some of the products listed have claims against other parasites. Refer to the Summary of Product Characteristics for each product for full details of the licensed indications.
‖ Treats only demodicosis but not sarcoptic mange.
NexGard Spectra® contains afoxolaner and milbemycin oxime. UK: POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: vetenquiries@boehringer-ingelheim.com. NexGard Spectra® is a registered trademark of Boehringer Ingelheim Animal Health France SCS, used under licence. ©2023 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: October 2023. UI-CAN-0129-2023. Use Medicines Responsibly.